Nature-based Intervention to Enhance Well-being

March 2, 2022 updated by: Hou Wai Kai, Education University of Hong Kong

Testing a New Protocol of Nature-based Intervention to Enhance Well-being: A Randomized Control Trial

The aim of the present study is to investigate the effectiveness of a nature-based intervention on adaptive psychological functioning. We compared a structured protocol with a high level of nature engagement and involvement of multiple sensory processes with a waitlist control group. We expected that participants in the structured protocol of nature contact will report higher levels of mental health and more positive work-related functioning immediately and three months after the interventions.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study aims to test the associations of nature contact with multiple dimensions of psychological functioning. A total of 90 university employees were randomly assigned to spend their lunch breaks on a (1) 30-minute structured protocol of nature contact and a (2) control group for 10 consecutive weekdays. Psychological distress, psychological well-being, and work-related psychological outcomes were assessed at baseline (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
90

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Hong Kong, China
        • The Education University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 years or older
  • Cantonese speaking
  • Full-time employment of The Education University of Hong Kong

Exclusion Criteria:

  • NA

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: Program Group
This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
Behavioral: Structured Protocol of Nature Contact
This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
NO_INTERVENTION: Waitlist control group
Participants who were randomly assigned to the waitlist control group were instructed to spend their usual half-hour lunch break in the office for consecutive 10 weekdays. Also, the waitlist control group was told to wait for at least three months before they took part in the structured protocol of nature contact.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change from baseline (T1) anxiety symptoms to post intervention (T2) and follow up (T3)
Time Frame: Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
The Chinese version of the 7-item Generalized Anxiety Disorder (GAD-7) was used to measure anxiety symptoms at all time points. Participants rated each item on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day) based on their experience in the past two weeks. Higher scores indicated greater severity of anxiety symptoms (range = 0-21).
Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Change from baseline (T1) depressive symptoms to post intervention (T2) and follow up (T3)
Time Frame: Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Depressive symptoms were measured using the Chinese version of the Patient Health Questionnaire-9 (PHQ-9) at T1, T2, and T3, respectively. Participants rated each item on a 4-point scale as in GAD-7. Higher scores indicate the greatest severity of the depressive symptoms (range 0-27).
Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Change from baseline (T1) perceived stress to post intervention (T2) and follow up (T3)
Time Frame: Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Perceived stress was assessed at all time points using the Chinese version of the 10-item Perceived Stress Scale (PSS-10). Participants reported their subjective stress in the past two weeks on a 5-point scale (0 = never, 4 = very often). Total scores ranged from 0 to 40, with higher scores indicating higher levels of perceived stress.
Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Change from baseline (T1) subjective well-being to post intervention (T2) and follow up (T3)
Time Frame: Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
The WHO-Five Well-being Index (WHO-5) consisted of five positively worded items. Participants were asked to report the presence of the five positive mental states in the past 2 weeks on a 6-point scale ranging from 0 (at no time) to 5 (all of the time).
Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Change from baseline (T1) satisfaction with life to post intervention (T2) and follow up (T3)
Time Frame: Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Satisfaction with Life Scale (SWLS) was used to assess participants' well-being with regard to satisfaction and fulfillment of their current state on a 4-point scale (1 = strongly disagree, 4 = strongly agree). The five items were summed, with higher scores indicating higher life satisfaction (range = 5-20).
Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Change from baseline (T1) positive affect to post intervention (T2) and follow up (T3)
Time Frame: Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
The 10-item positive affect subscale of Chinese Affect Scale (CAS-PA) assessed frequency of positive emotional experience in the past 2 weeks on a 5-point scale (0 = not at all, 4 = all the time).
Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Change from baseline (T1) burnout to post intervention (T2) and follow up (T3)
Time Frame: Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Burnout was measured using the Chinese version of the 14-item Maslach Burnout Inventory-General Survey (MBI-GS) at all time points. Participants rated how often they had different experiences of burnout in the past two weeks on a 7-point scale (0 = never, 6 = always). The scale consisted of five questions on emotional exhaustion, four on cynicism, and five on professional efficacy.
Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
Change from baseline (T1) work engagement to post intervention (T2) and follow up (T3)
Time Frame: Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).
The Chinese version of the 17-item Utrecht Work Engagement Scale (UWES) was used to assess vigor, dedication, and absorption at work at all time points. Participants indicated the frequency of these experiences at work in the past two weeks on a 7-point scale (0 = never, 6 = always).
Before the intervention (T1), the day after the 10-day intervention (T2), and three months after the intervention (T3).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Education University of Hong Kong

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Wai Kai Hou, PhD, The Education University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 9, 2019

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 30, 2021

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 22, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 2, 2022

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 11, 2022

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 11, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 2, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 04465
  • 2019-2020-0191 (OTHER: Human Research Ethics Committee)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will be available on request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings